Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans

Butler et al's study involved eight subjects - seven were treated with DPP-IV inhibitors and one with a GLP-1 agonist.

Incretin therapy resulted in a marked expansion of the exocrine and endocrine pancreatic compartments, the former being accompanied by increased proliferation and dysplasia, the latter by α cell hyperplasia with the potential for evolution into Glucagon-producing neuroendocrine tumors.

Read more.

Read a blog on the issue

Diabetesbible is for health professionals